Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)
- Citation:
- Cancer vol 126 (24) 5311-5318
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 10
- Parents:
- 2908
- Children:
- None
- Pharmas:
- Ipsen and Exelixis
- Grants:
- U10CA180821, U10CA180882, UG1CA189823
- Corr. Author:
- Authors:
- Ronald C. Chen Toni K. Choueiri Marion Feuilly Jie Meng Johanna Lister Florence Marteau Aaron D. Falchook Michael J. Morris Daniel J. George Darren R. Feldman
- Networks:
- FL023, KANSAS, LAPS-MA036, LAPS-NC010, LAPS-NY016
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- carcinoma, protein tyrosine kinases, quality of life, renal cell